Physician profile
Yang Wang
NPI 1073810966
$3,203.11
in general payments reported to CMS, 2019-2025
48 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $130 · 2021: $28.59 · 2022: $60.62 · 2023: $326 · 2024: $681 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370 · Education: $88.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,369.58 |
| Education | $88.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $303.37 | 2019-2025 | Erleada, Rybrevant, Balversa |
| Novartis Pharmaceuticals Corporation | $282.80 | 2019-2025 | |
| Daiichi Sankyo INC. | $225.13 | 2022-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $204.21 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $151.45 | 2019-2025 | Opdualag, Opdivo |
| Exelixis INC. | $121.14 | 2019-2025 | Cabometyx |
| Sobi, INC | $115.89 | 2025 | |
| Beone Medicines USA, INC. | $101.30 | 2025 | Tevimbra, Brukinsa |
| Glaxosmithkline, LLC. | $98.29 | 2023-2025 | Ojjaara |
| Amgen INC. | $87.29 | 2019-2024 | Lumakras |
| Astrazeneca Pharmaceuticals Lp | $82.57 | 2019-2024 | Enhertu, Lynparza |
| Seagen INC. | $69.70 | 2020-2023 | Adcetris |
| Gilead Sciences, INC. | $69.34 | 2024-2025 | Trodelvy |
| Kite Pharma, INC. | $68.52 | 2025 | Yescarta |
| Merck Sharp & Dohme LLC | $67.80 | 2023-2025 | Keytruda, Lynparza |
Show all 47 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yang Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.